Xeomin cleared for pediatric upper limb spasticity in cerebral palsy

Sponsor

Merz Therapeutics

Drug

Xeomin · incobotulinumtoxinA

Indication

Upper-limb spasticity in pediatric patients aged 2 and older with cerebral palsy

FDA approved Merz Therapeutics' Xeomin (incobotulinumtoxinA) for the treatment of upper-limb spasticity in pediatric patients aged 2 and older with cerebral palsy. Xeomin was previously approved for adult upper-limb spasticity in 2010; this label expansion extends the indication into the largest population for which upper-limb spasticity intervention is prescribed.